A novel enzymatic means to confirm correct and safe nasogastric tube placement

一种新的酶法来确认正确和安全的鼻胃管放置

• 批准号: 102134
• 金额: $ 105.67万
• 依托单位: INGENZA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102134
• 关键词: novel; enzymatic; means; confirm; correct

Our pilot study (n= 23, including 15 patients on antacid medications) found this new test was 100% accurate. The results, if validated further in this proposed, thorough clinical evaluation and scientific device development programme, mean that the new test would reduce feeding incidents due to misinterpretation of pH strip and X-ray results and cut the need for chest x-rays by about a third. Wider benefits to healthcare providers and patients include 1) significant cost savings (£1 per enzymatic test versus £120 per x-ray); 2) reduced risk of misdiagnosis of misplaced NG tubes; 3) biopsychosocial improvements for patients, 4) greater confidence and reliability in nursing care and 5) improved patient care and safety. Upon validation, there would be clear potential to apply related enzymatic marker detection more broadly to detect disease, health monitoring and infection.

我们的初步研究(n=23，包括15名服用抗酸药物的患者)发现，这种新的测试是100%准确的。如果这些结果在这个拟议的、彻底的临床评估和科学设备开发计划中得到进一步验证，意味着新的测试将减少由于误解pH试纸和X光结果而导致的喂养事件，并将胸部X光的需求减少约三分之一。对医疗保健提供者和患者更广泛的好处包括1)显著节省成本(每次酶检测1 GB，而每次X光为120 GB)；2)降低误诊错误的NG管的风险；3)改善患者的生物心理社会状况，4)提高护理的信心和可靠性，5)改善患者的护理和安全性。在验证之后，将有明显的潜力更广泛地应用相关的酶标记检测来检测疾病、健康监测和感染。